TD Asset Management Inc decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 11.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 202,092 shares of the company's stock after selling 26,468 shares during the period. TD Asset Management Inc owned 0.31% of Kymera Therapeutics worth $5,531,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the business. Neo Ivy Capital Management bought a new position in Kymera Therapeutics during the first quarter valued at approximately $395,000. KBC Group NV boosted its stake in Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after buying an additional 328 shares during the last quarter. Rhumbline Advisers boosted its stake in Kymera Therapeutics by 9.0% during the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after buying an additional 5,771 shares during the last quarter. GAMMA Investing LLC boosted its stake in Kymera Therapeutics by 3,851.5% during the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after buying an additional 6,509 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in Kymera Therapeutics by 12.6% during the fourth quarter. California State Teachers Retirement System now owns 36,839 shares of the company's stock valued at $1,482,000 after buying an additional 4,131 shares during the last quarter.
Wall Street Analyst Weigh In
KYMR has been the subject of a number of research reports. Jefferies Financial Group set a $64.00 price target on Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday, June 25th. B. Riley upgraded Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price objective on the stock in a research report on Wednesday. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research report on Monday, June 2nd. Guggenheim restated a "buy" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Finally, BTIG Research restated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Two analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $59.11.
Read Our Latest Research Report on Kymera Therapeutics
Insider Activity at Kymera Therapeutics
In other Kymera Therapeutics news, Director Elena Ridloff sold 12,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer owned 660,482 shares in the company, valued at $32,363,618. The trade was a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,349 shares of company stock worth $2,334,301 over the last three months. Corporate insiders own 16.01% of the company's stock.
Kymera Therapeutics Stock Down 1.8%
KYMR stock opened at $42.96 on Friday. The business's fifty day simple moving average is $43.85 and its two-hundred day simple moving average is $36.57. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $53.27. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -13.86 and a beta of 2.18.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same quarter last year, the firm posted ($0.69) earnings per share. The business's revenue was up 114.6% compared to the same quarter last year. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.
About Kymera Therapeutics
(
Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
